A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab
Mathieu C, Wiedeman A, Cerosaletti K, Long SA, Serti E, Cooney L, Vermeiren J, Caluwaerts S, Van Huynegem K, Van Huynegem K, Steidler L, Blomme S, Rottiers P, Nepom GT, Herold KC, AG019-T!D-101 Trial Investigators
Mathieu C, Wiedeman A, Cerosaletti K, Long SA, Serti E, Cooney L, Vermeiren J, Caluwaerts S, Van Huynegem K, Van Huynegem K, Steidler L, Blomme S, Rottiers P, Nepom GT, Herold KC, AG019-T!D-101 Trial Investigators (2024). A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab. Diabetologia, 67 (1), 27-41.
Follow-up to Adolescence after Early Peanut Introduction for Allergy Prevention
Du Toit G, Huffaker MF, Radulovic S, Feeney M, Fisher HR, Byron M, Dunaway L, Calatroni A, Johnson M, Foong RX, Marques-Mejias A, Bartha I, Basting M, Brough HA, Baloh C, Laidlaw TM, Bahnson HT, Roberts G, Plaut M, Wheatley LM, Lack G, Immune Tolerance Network LEAP-Trio Trial Team
Du Toit G, Huffaker MF, Radulovic S, Feeney M, Fisher HR, Byron M, Dunaway L, Calatroni A, Johnson M, Foong RX, Marques-Mejias A, Bartha I, Basting M, Brough HA, Baloh C, Laidlaw TM, Bahnson HT, Roberts G, Plaut M, Wheatley LM, Lack G, Immune Tolerance Network LEAP-Trio Trial Team (2024). Follow-up to Adolescence after Early Peanut Introduction for Allergy Prevention. NEJM Evid, Epub ahead of print.
Immunosuppression withdrawal in living-donor renal transplant recipients following induction with antithymocyte globulin and rituximab: Results of a prospective clinical trial
Markmann JF, Burrell BE, Bromberg JS, Hartono C, Kaufman DB, Possselt AM, Naji A, Bridges ND, Breeden C, Kanaparthi S, Pardo J, Kopetskie H, Mason K, Lim N, Chandran S.
Markmann JF, Burrell BE, Bromberg JS, Hartono C, Kaufman DB, Possselt AM, Naji A, Bridges ND, Breeden C, Kanaparthi S, Pardo J, Kopetskie H, Mason K, Lim N, Chandran S. (2024). Immunosuppression withdrawal in living-donor renal transplant recipients following induction with antithymocyte globulin and rituximab: Results of a prospective clinical trial.. Am J Transplant., Epub ahead of print.
Defining the window of opportunity and the target populations to prevent peanut allergy
Roberts, G. Bahnson. HT. Du Toit, G. O’Rourk, C. Sever, M, Brittain, E. Plaut, M. Lack, G.
Roberts, G. Bahnson. HT. Du Toit, G. O’Rourk, C. Sever, M, Brittain, E. Plaut, M. Lack, G. (2023). Defining the window of opportunity and the target populations to prevent peanut allergy. J Allergy Clin Immunol., 151 (5), 1329-1336.
In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age.
Suprun M, Bahnson HT, Du Toit G, Lack G, Suarez-Farinas M, Sampson HA.
Suprun M, Bahnson HT, Du Toit G, Lack G, Suarez-Farinas M, Sampson HA. (2023). In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age.. Allergy, 78 (2), 586-589.
Omics-Oriented Research illustrated with the LEAP Study and the OASIS Bioinformatics Tool.
Baloh CH, Kanchan K, Shankar G, Nepom GT, Mathias RA, Perry JA.
Baloh CH, Kanchan K, Shankar G, Nepom GT, Mathias RA, Perry JA. (2023). Omics-Oriented Research illustrated with the LEAP Study and the OASIS Bioinformatics Tool.. The Journal of Allergy and Clinical Immunology, 151 (2), 416-419.
Developing a Prediction Model for Determination of Peanut Allergy Status in the LEAP Studies
Sever ML, Calatroni A, Roberts G, Du Toit G, Bahnson HT, Radulovic S, Larson D, Byron M, Santos AF, Huffaker MF, Wheatley LM, Lack G.
Sever ML, Calatroni A, Roberts G, Du Toit G, Bahnson HT, Radulovic S, Larson D, Byron M, Santos AF, Huffaker MF, Wheatley LM, Lack G. (2023). Developing a Prediction Model for Determination of Peanut Allergy Status in the LEAP Studies. J Allergy Clin Immunol Pract, Epub ahead of print.
Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses
Logan K, Bahnson HT, Ylescupidez A, Beyer K, Bellach J, Campbell DE, Craven J, Du Toit G, Clare Mills EN, Perkin MR, Roberts G, van Ree R, Lack G
Logan K, Bahnson HT, Ylescupidez A, Beyer K, Bellach J, Campbell DE, Craven J, Du Toit G, Clare Mills EN, Perkin MR, Roberts G, van Ree R, Lack G (2023). Early introduction of peanut reduces peanut allergy across risk groups in pooled and causal inference analyses. Allergy, 78 (5), 1307-1318.
Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy
Altman MC, Segnitz RM, Larson D, Jayavelu ND, Smith MT, Patel S, Scadding GW, Qin T, Sanda S, Steveling E, Eifan AO, Penagos M, Jacobson MR, Parkin RV, Shamji MH, Togias A, Durham SR
Altman MC, Segnitz RM, Larson D, Jayavelu ND, Smith MT, Patel S, Scadding GW, Qin T, Sanda S, Steveling E, Eifan AO, Penagos M, Jacobson MR, Parkin RV, Shamji MH, Togias A, Durham SR (2023). Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy. J Allergy Clin Immunol, 152 (5), 1247-1260.
Recent progress in the genetic and epigenetic underpinnings of atopy
Baloh C, Mathias R
Baloh C, Mathias R (2023). Recent progress in the genetic and epigenetic underpinnings of atopy. Journal of Allergy and Clinical Immunology, 151 (1), 60-69.
Incorporating genetics in identifying peanut allergy risk and tailoring allergen immunotherapy: A perspective on the genetic findings from the LEAP trial
Huffaker, M. F., Kanchan, K., Bahnson, H. T., Baloh, C., Lack, G., Nepom, G. T., & Mathias, R. A
Huffaker, M. F., Kanchan, K., Bahnson, H. T., Baloh, C., Lack, G., Nepom, G. T., & Mathias, R. A (2023). Incorporating genetics in identifying peanut allergy risk and tailoring allergen immunotherapy: A perspective on the genetic findings from the LEAP trial. Journal of Allergy and Clinical Immunology, Epub ahead of print.
Autoreactive plasmablasts after B cell depletion with rituximab and relapses in ANCA-associated vasculitis
Berti A, Hillion S, Konig MF, Casal Moura M, Hummel AM, Carmona E, Peikert T, Fervenza FC, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, Brunetta P, St Clair EW, Harris KM, Stone JH, Grandi G, Pers JO, Specks U, Cornec D.
Berti A, Hillion S, Konig MF, Casal Moura M, Hummel AM, Carmona E, Peikert T, Fervenza FC, Kallenberg CGM, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, Brunetta P, St Clair EW, Harris KM, Stone JH, Grandi G, Pers JO, Specks U, Cornec D. (2023). Autoreactive plasmablasts after B cell depletion with rituximab and relapses in ANCA-associated vasculitis. Arthritis Rheumatol, 75 (5), 736-747.
Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3
Moura MC, Thompson GE, Nelson DR, Fussner LA, Hummel AM, Jenne DE, Emerling D, Fervenza FC, Kallenberg CGM, Langford CA, McCune WJ, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Ytterberg SR, Stone JH, Robinson WH, Specks U
Moura MC, Thompson GE, Nelson DR, Fussner LA, Hummel AM, Jenne DE, Emerling D, Fervenza FC, Kallenberg CGM, Langford CA, McCune WJ, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Ytterberg SR, Stone JH, Robinson WH, Specks U (2023). Activation of a Latent Epitope Causing Differential Binding of Anti-Neutrophil Cytoplasmic Antibodies to Proteinase 3. Arthritis Rheumatol, 75 (5), 748-759.
Risk factors for serious infections in ANCA-associated vasculitis
Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, St Clair W, Fervenza F, Geetha D, Monach P, Jayne D, Smith RM, Rosenkranz A, Specks U, Stone JH, Kronbichler A; RAVE−ITN Research Group.
Odler B, Riedl R, Gauckler P, Shin JI, Leierer J, Merkel PA, St Clair W, Fervenza F, Geetha D, Monach P, Jayne D, Smith RM, Rosenkranz A, Specks U, Stone JH, Kronbichler A; RAVE−ITN Research Group. (2023). Risk factors for serious infections in ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 82 (5), 681-687.
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC; Type 1 Diabetes TrialNet Study Group.
Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, Gottlieb PA, Greenbaum CJ, Haller MJ, Krischer JP, Libman IM, Linsley PS, Long SA, Lord SM, Moore DJ, Moore WV, Moran AM, Muir AB, Raskin P, Skyler JS, Wentworth JM, Wherrett DK, Wilson DM, Ziegler AG, Herold KC; Type 1 Diabetes TrialNet Study Group. (2023). Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial. . Diabetes Care., 46 (5), 1005-1013.
Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance
Sykes M, Chandran S, Kawai T, Levitsky J, Mapara M, Mathew J, Thomson A, Yamada K.
Sykes M, Chandran S, Kawai T, Levitsky J, Mapara M, Mathew J, Thomson A, Yamada K. (2023). Meeting Report: The Fifth International Samuel Strober Workshop on Clinical Immune Tolerance. Transplantation, 107 (3), 564-569.
Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses
Duan, M., Nguyen, D. C., Joyner, C. J., Saney, C. L., Tipton, C. M., Andrews, J., Lonial, S., Kim, C., Hentenaar, I., Kosters, A., Ghosn, E., Jackson, Knechtle, Maruthamuthu, Chandran, Martin, T., Rajalingam, R., Vincenti, F., Breeden, Sanz, Gibson, G., Lee, F. E.
Duan, M., Nguyen, D. C., Joyner, C. J., Saney, C. L., Tipton, C. M., Andrews, J., Lonial, S., Kim, C., Hentenaar, I., Kosters, A., Ghosn, E., Jackson, Knechtle, Maruthamuthu, Chandran, Martin, T., Rajalingam, R., Vincenti, F., Breeden, Sanz, Gibson, G., Lee, F. E. (2023). Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses.. Cell Reports, 42 (7), 112682.
Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes
Balmas E, Chen J, Hu AK, DeBerg HA, Rosasco MG, Gersuk VH, Serti E, Speake C, Greenbaum CJ, Nepom GT, Linsley P. Cerosaletti
Balmas E, Chen J, Hu AK, DeBerg HA, Rosasco MG, Gersuk VH, Serti E, Speake C, Greenbaum CJ, Nepom GT, Linsley P. Cerosaletti (2023). Islet-autoreactive CD4+ T cells are linked with response to alefacept in type 1 diabetes. JCI Insight, 8 (21), e167881.
Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes
Delgado AL, Preston-Hurlburt P, Lim N, Sumida TS, Long SA, McNamara J, Serti E, Higdon L, Herold KC
Delgado AL, Preston-Hurlburt P, Lim N, Sumida TS, Long SA, McNamara J, Serti E, Higdon L, Herold KC (2023). Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes. medRxiv, Epub ahead of print.
Th2 cell clonal expansion at diagnosis in human type 1 diabetes
Narsale A, Almanza F, Tran T, Lam B, Seo D, Vu A, Long SA, Cooney L, Serti E, Davies JD
Narsale A, Almanza F, Tran T, Lam B, Seo D, Vu A, Long SA, Cooney L, Serti E, Davies JD (2023). Th2 cell clonal expansion at diagnosis in human type 1 diabetes. Clinical Immunology, 257, 109829.
Self-reactive germline-like TCR alpha chains shared between blood and pancreas
Linsley P, Nakayama M, Balmas E, Chen J, Pour F, Bansal S, Serti E, Speake C, Pugliese A, Cerosaletti K
Linsley P, Nakayama M, Balmas E, Chen J, Pour F, Bansal S, Serti E, Speake C, Pugliese A, Cerosaletti K (2023). Self-reactive germline-like TCR alpha chains shared between blood and pancreas. Res Sq, NLM Preprint.
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy
Calise J, DeBerg HA, Garabatos N, Khosa S, Bajzik V, Botero Calderon L, Aldridge K, Rosasco M, Ferslew BC, Zhu T, Smulders R, Wheatley LM, Laidlaw TM, Qin T, Chichili GR, Adelman DC, Farrington M, Robinson D, Jeong D, Jones SM, Sanda S, Larson D, Kwok WW, Baloh C, Nepom GT, Wambre E, IMPACT investigators
Calise J, DeBerg HA, Garabatos N, Khosa S, Bajzik V, Botero Calderon L, Aldridge K, Rosasco M, Ferslew BC, Zhu T, Smulders R, Wheatley LM, Laidlaw TM, Qin T, Chichili GR, Adelman DC, Farrington M, Robinson D, Jeong D, Jones SM, Sanda S, Larson D, Kwok WW, Baloh C, Nepom GT, Wambre E, IMPACT investigators. (2023) Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy. J Allergy Clin Immunol, 152 (1), 155-166.e9.
Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study
Jones SM, Nadeau KC, Nowak-Węgrzyn A, Wood RA, Sampson HA, Scurlock AM, Chinthrajah RS, Wang J, Pesek RD, Sindher SB, Kulis M, Spain K, Babineau DC, Chin H, Laurienzo-Panza J, Yan R, Qin T, Whitehouse D, Sever ML, Sanda S, Plaut M, Wheatley LM, Burks AW, Immune Tolerance Network
Jones SM, Nadeau KC, Nowak-Węgrzyn A, Wood RA, Sampson HA, Scurlock AM, Chinthrajah RS, Wang J, Pesek RD, Sindher SB, Kulis M, Spain K, Babineau DC, Chin H, Laurienzo-Panza J, Yan R, Qin T, Whitehouse D, Sever ML, Sanda S, Plaut M, Wheatley LM, Burks AW, Immune Tolerance Network (2022). Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet, 399 (10322), 359-371.
HLA alleles and sustained peanut consumption promote IgG4 responses in subjects protected from peanut allergy
Kanchan K, Grinek S, Bahnson HT, Ruczinski I, Shankar G, Larson D, Du Toit G, Barnes KC, Sampson HA, Suarez-Farinas M, Lack G, Nepom GT, Cerosaletti K, Mathias RA
Kanchan K, Grinek S, Bahnson HT, Ruczinski I, Shankar G, Larson D, Du Toit G, Barnes KC, Sampson HA, Suarez-Farinas M, Lack G, Nepom GT, Cerosaletti K, Mathias RA (2022). HLA alleles and sustained peanut consumption promote IgG4 responses in subjects protected from peanut allergy. J Clin Invest, 132 (1).
Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses
Bajzik V, DeBerg HA, Garabatos N, Rust BJ, Obrien KK, Nguyen QA, O'Rourke C, Smith A, Walker AH, Quinn C, Gersuk VH, Farrington M, Jeong D, Vickery BP, Adelman DC, Wambre E
Bajzik V, DeBerg HA, Garabatos N, Rust BJ, Obrien KK, Nguyen QA, O'Rourke C, Smith A, Walker AH, Quinn C, Gersuk VH, Farrington M, Jeong D, Vickery BP, Adelman DC, Wambre E (2022). Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses. Allergy, Epub ahead of print.
Early intervention and prevention of allergic diseases
Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR
Brough HA, Lanser BJ, Sindher SB, Teng JMC, Leung DYM, Venter C, Chan SM, Santos AF, Bahnson HT, Guttman-Yassky E, Gupta RS, Lack G, Ciaccio CE, Sampath V, Nadeau KC, Nagler CR. (2022). Early intervention and prevention of allergic diseases. Allergy, 77 (2), 416-441.
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial
Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, Baroody F, Moss MH, Nelson H, Burbank AJ, Hernandez ML, Peden D, Saini S, Tilles S, Hussain I, Whitehouse D, Qin T, Villarreal M, Sever M, Wheatley LM, Nepom GT, Sanda S
Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, Baroody F, Moss MH, Nelson H, Burbank AJ, Hernandez ML, Peden D, Saini S, Tilles S, Hussain I, Whitehouse D, Qin T, Villarreal M, Sever M, Wheatley LM, Nepom GT, Sanda S. (2022). Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: a randomized controlled trial. Journal of Allergy and Clinical Immunology.
Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy
Smeekens JM, Baloh C, Lim N, Larson D, Qin T, Wheatley L, Kim EH, Jones SM, Burks AW, Kulis MD
Smeekens JM, Baloh C, Lim N, Larson D, Qin T, Wheatley L, Kim EH, Jones SM, Burks AW, Kulis MD. (2022). Peanut-Specific IgG4 and IgA in Saliva Are Modulated by Peanut Oral Immunotherapy. The Journal of Allergy and Clinical Immunology, Epub ahead of print.
Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years
Grinek S, Suprun M, Raghunathan R, Tomalin LE, Getts R, Bahnson T, Lack G, Sampson HA, Suarez-Farinas M.
Grinek S, Suprun M, Raghunathan R, Tomalin LE, Getts R, Bahnson T, Lack G, Sampson HA, Suarez-Farinas M. (2022). Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years. Int Arch Allergy Immunol., Epub ahead of print, 1-6.
Biomarkers and mechanisms of tolerance induction in food allergic patients drive new therapeutic approaches
Baloh CH, Huffaker MF and Laidlaw T.
Baloh CH, Huffaker MF and Laidlaw T. (2022). Biomarkers and mechanisms of tolerance induction in food allergic patients drive new therapeutic approaches. Front Immunol, 13.
